Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge
January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses,...
read more
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
New Suspicious Lesions on Breast MRI in Neoadjuvant Therapy
January 15, 2021 — According to ARRS' American Journal of Roentgenology (AJR), new suspicious findings occurred in 5.5...
read more
Carestream Health showcased its expertise in medical imaging across an array of clinical specialties at the virtual meeting of the Radiological Society of North America (RSNA). From bedside imaging solutions to scalable X-ray room systems, the company demonstrated its growing product portfolio that fits budget, workflow, safety and space requirements.
News | Digital Radiography (DR) | January 14, 2021
Carestream Focused on Innovation in Diagnostic Imaging Portfolio at Virtual RSNA
January 14, 2021 — Carestream Health showcased its expertise in medical imaging across an array of clinical specialties...
read more
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
Inpatient Mammograms Can Reduce Disparities in Breast Cancer Screening Rates
January 14, 2021 — Completing cancer screening tests, such as mammograms, can be challenging for low-income people, who...
read more
Multidisciplinary functionality supports high-capacity utilization and economic efficiency
News | Mobile C-Arms | January 14, 2021
FDA Clears Siemens Healthineers Cios Flow Mobile C-arm System 
January 14, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Cios Flow...
read more
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
US Prostate Cancer Nuclear Medicine Diagnostics Market Outlook
January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast...
read more
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
DenseBreast-info Launches Updated Website
January 13, 2021 — DenseBreast-info.org (DB-I) invites health providers seeking the most up-to-date medically-sourced...
read more
Use of telehealth jumped sharply during the first months of the coronavirus pandemic shutdown, with the approach being used more often for behavioral health services than for medical care, according to a new RAND Corporation study.

Getty Images

News | Teleradiology | January 13, 2021
Use of Telehealth Jumped as Pandemic Shutdown Began
January 13, 2021 — Use of telehealth jumped sharply during the first months of the coronavirus pandemic shutdown, with...
read more
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
Therapixel receives CE mark for AI-based software MammoScreen
January 12, 2021 — Therapixel announced that MammoScreen has successfully obtained the CE mark. After having received...
read more
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
FDA Releases AI/Machine Learning Action Plan
January 12, 2021 — The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine...
read more
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
Cardiac MRI Shows Lower Degrees of Myocarditis in Athletes Recovered from COVID-19
January 11, 2021 — In a letter published in the December issue of the American Heart Association's medical journal ...
read more
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
MRI Frequently Underestimates Tumor Size in Prostate Cancer
January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic...
read more
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
Focused Ultrasound Shows Promise for Parkinson's Disease
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s...
read more
The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

Getty Images

News | Coronavirus (COVID-19) | January 08, 2021
FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Healthcare Providers
January 8, 2021 — The U.S. Food and Drug Administration is alerting clinical laboratory staff and healthcare providers...
read more
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
Mirion Technologies Acquires Sun Nuclear Corporation
January 8, 2021 — Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement...
read more
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
New Mammogram Measures of Breast Cancer Risk Could Revolutionize Screening
January 6, 2021 — World-first techniques for predicting breast cancer risk from mammograms that were developed in...
read more
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers
January 6, 2021 — Hologic, Inc., a global leader in women's health, announced today that it has agreed to acquire...
read more
In this roundtable discussion hosted by ITN Editorial Director Melinda Taschetta-Millane, three medical experts will discuss the impact COVID-19 had on the industry in 2020, as well as projections for the industry in 2021.
Webinar | Coronavirus (COVID-19) | January 06, 2021
Editorial Roundtable Series: COVID-19: Economic Impact on Radiology and What to Expect in 2021
2020 was an unprecedented year, as the world grappled with a global pandemic, economic depression, and workflow...
read more
Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. #AI #AIhealthcare #AIecho

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

News | Artificial Intelligence | January 06, 2021
FDA Clears Ultromics Echocardiography AI for Auto Identification of Coronary Artery Disease
January 6, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Ultromics' EchoGo Pro, an artificial...
read more
OptumInsight and Change Healthcare combine to advance a more modern, information and technology-enabled healthcare platform

Getty Images

News | Information Technology | January 06, 2021
Optum Set to Purchase Change Healthcare
January 6, 2020 — Optum, a diversified health services company and part of UnitedHealth Group, and Change Healthcare, a...
read more
© Copyright Wainscot Media. All Rights Reserved.